Advanced Medical Solutions Group (LSE:AMS) Risk Assessment

View and export this data going back to 2002. Start your Free Trial

What is Advanced Medical Solutions Group Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Advanced Medical Solutions Group is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Advanced Medical Solutions Group's Risk Assessment

For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced Medical Solutions Group's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Advanced Medical Solutions Group's Risk Assessment falls into.

Advanced Medical Solutions Group (LSE:AMS) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Advanced Medical Solutions Group Risk Assessment Related Terms

Thank you for viewing the detailed overview of Advanced Medical Solutions Group's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced Medical Solutions Group (LSE:AMS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Medical Solutions Group PLC (LSE:AMS) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

AMS.GB:UK AQA:Germany

Address

Premier Park, 33 Road One, Winsford Industrial Estate, Winsford, Cheshire, GBR, CW7 3RT

Website

https://www.admedsol.com

U.K.-based Advanced Medical Solutions was founded in 1991 to design, develop, and manufacture advanced wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The firm derives approximately 60% of total revenue from branded products, with nonbranded contributing 40%.